Title:Role of Nanotechnology for Enzyme Replacement Therapy in Lysosomal Diseases. A Focus on Gaucher’s Disease
Volume: 23
Issue: 9
Author(s): L. Martín-Banderas, M.A. Holgado, M. Durán-Lobato, J.J. Infante, J. Álvarez-Fuentes, M. Fernández-Arévalo
Affiliation:
关键词:
溶酶体贮积病,高雪氏病,酶替代疗法,纳米技术,定向
摘要: Lysosomal storage diseases (LSDs) comprise a group of rare inherited chronic
syndromes that cause deficiency of specific native enzymes within the lysosomes. The macromolecular
compounds that are usually catabolized by lysosomal enzymes are accumulated
within these organelles, causing progressive damage to tissues, skeleton and organs and, in
several cases, the central nervous system (CNS). The damage caused by substrate accumulation
finally results in physical deterioration, functional impairment and potential death. Up to date, the most
promising therapy for most LSDs is enzyme-replacement therapy (ERT), which provides patients with the
corresponding active enzyme. However, these enzymes do not have enough stability in blood, the treatment
must be therefore periodically administrated by i.v. infusion under medical supervision, and immunogenicity
issues are frequent. In addition, affected areas within the CNS, where the blood-brain barrier (BBB) is a major
obstacle, cannot be reached by the enzymes. Nanotechnology can provide useful carriers to successfully protect
and preserve enzymes, and transport them through the BBB towards brain locations. Several strategies
based on targeting specific receptors on the BBB have led to nanoparticles that successfully carry sensitive
molecules to the brain. Then, the main LSDs are described and a thorough review of nanotechnology strategies
for brain delivery studied up to date is presented.